Prothena Corp. (NASDAQ: PRTA) reported Q4 EPS of ($0.56), $0.38 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $200 thousand.

Net cash used in operating and investing activities was $22.5 million in the fourth quarter and $30.0 million for the full year 2018; quarter-end cash and restricted cash position of $431.7 million provides funding to advance neuroscience pipeline

For earnings history and earnings-related data on Prothena Corp. (PRTA) click here.